UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2011
INTERMUNE, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction |
0-29801 (Commission |
94-3296648 (IRS Employer |
3280 Bayshore Boulevard
Brisbane, CA 94005
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (415) 466-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On September 12, 2011, InterMune, Inc. hosted a conference call and webcast at 8:30 a.m. (Eastern Time) that provided details on the commercial launch of Esbriet® (pirfenidone) in Germany beginning on September 15, 2011. InterMune announced that based on negotiations with German access and reimbursement authorities, the gross ex-factory price for an annual course of Esbriet will be €36,000, with the net price for Esbiret estimated at €30,240. InterMune also noted that pricing in other European countries remains subject to negotiation with the relevant reimbursement authorities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 12, 2011 | INTERMUNE, INC. | |||||
| By: | /s/ John C. Hodgman | |||||
| John C. Hodgman | ||||||
| Senior Vice President of Finance Administration and Chief Financial Officer | ||||||